Stock Comparison

BEAM vs LLY

Beam Therapeutics Inc vs Eli Lilly and Co

The Verdict

BEAM takes this one.

Winner

BEAM

Beam Therapeutics Inc

9.1

out of 10

Hidden Gem

LLY

Eli Lilly and Co

0.5

out of 10

Distressed

Head-to-Head

$2.4B

Market Cap

$965.0B

0.0

P/E Ratio

52.6

-744.4%

Profit Margin

N/A

-47.2%

Return on Equity

N/A

0.2

Debt-to-Equity

N/A

Aggressive

Overall Risk

Moderate

9.1

DVR Score

0.5

The Deep Dive

BEAM9.1/10

Beam Therapeutics retains a high 10x growth potential, driven by its cutting-edge base editing platform, which continues to demonstrate significant promise for precision genetic cures. Recent positive developments, including the selection of an optimal dose for BEAM-302 in Phase 1/2 trials and the unveiling of the BEAM-304 PKU program (IND expected 2026), highlight strong execution and pipeline ex...

Full BEAM Analysis

LLY0.5/10

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Full LLY Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.